European Journal of Rheumatology is a premier, peer-reviewed journal that has been paving the way for innovative research and in-depth analysis in the field of rheumatology since its launch. Published by AVES, this Open Access journal has been accessible to researchers, professionals, and students worldwide since 2014, promoting the sharing of valuable knowledge on rheumatic diseases and their treatment. With an ISSN of 2147-9720 and an E-ISSN of 2148-4279, it provides a prominent platform for groundbreaking studies and clinical evaluations that bridge scientific discovery with practical application. The journal’s mission is to enhance the understanding of rheumatological conditions and facilitate advancements in therapeutic strategies, making it an essential resource for anyone devoted to the improvement of patient care in this dynamic field. The European Journal of Rheumatology is committed to upholding the highest standards of scholarly publishing and aims to foster collaboration among researchers and practitioners across Europe and beyond.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Therapeutic Advances in Musculoskeletal Disease is a premier, peer-reviewed journal published by SAGE Publications Ltd, focusing on the latest advancements in the understanding and treatment of musculoskeletal disorders. Since becoming an Open Access journal in 2019, it has significantly broadened its reach, providing researchers, clinicians, and practitioners with unfettered access to high-quality studies and reviews from 2009 to 2024. With an impressive impact factor reflected by its Q1 rank in Orthopedics and Sports Medicine and Q2 rank in Rheumatology for 2023, the journal occupies a critical position within its field. Ranked #31 out of 321 in Orthopedics and Sports Medicine and #17 out of 73 in Rheumatology on Scopus, it emphasizes both the clinical and scientific aspects of musculoskeletal health. This journal serves as a vital resource for advancing knowledge, encouraging collaboration, and fostering innovative treatment methods within the musculoskeletal community.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.

Reumatologia is a dedicated open-access journal published by TERMEDIA PUBLISHING HOUSE LTD that has been serving the global scientific community since 2005. The journal focuses on the fields of Rheumatology, Immunology, and Allergy, providing a rich platform for researchers and practitioners to share innovative findings, clinical insights, and methodologies. With its roots tracing back to the early 1960s and a steady convergence of quality content through 2024, Reumatologia has secured a place in the academic landscape, currently holding a Q4 rating in Immunology and a Q3 rating in both Immunology and Allergy and Rheumatology categories for 2023. While the journal ranks #42 out of 73 in the Medicine - Rheumatology category, its open-access model ensures that research is widely disseminated, enhancing visibility and accessibility to vital knowledge that shapes therapeutic practices. Located in Poznan, Poland, Reumatologia remains a pivotal source of credible research, fostering collaboration among academics, healthcare professionals, and students internationally.

Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders, published by SAGE PUBLICATIONS LTD, is an esteemed open-access journal dedicated to advancing knowledge in the field of rheumatology and related immunological disorders. Since its inception in 2008, the journal has provided a platform for researchers and clinicians from around the world to disseminate cutting-edge studies and insights into arthritis and musculoskeletal conditions. Based in New Zealand, this journal has maintained a commendable standing in academic circles, evidenced by its Q3 quartile rankings in both Immunology and Allergy and Rheumatology categories for 2023, alongside respectable Scopus rankings. The journal serves as a vital resource for healthcare professionals, researchers, and students, facilitating enhanced understanding and treatment of musculoskeletal disorders through high-quality research and peer-reviewed articles. With a focus on fostering interdisciplinary collaboration and innovation in the field, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is essential reading for those committed to improving patient outcomes and advancing scientific knowledge.

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.